Compare AstraZeneca plc (AZN) vs EPAM Systems Inc (EPAM) Price & Performance

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

EPAM trades at $98.20, up 0.85% on the day, but remains in a bearish technical trend with support near $96 and resistance at $99. The company reported strong Q2 2026 earnings of $3.38 per share, beating estimates, but lowered its full-year revenue guidance due to slower North American growth. Valuation metrics appear attractive with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net income margin of 7.15%.

The outlook is mixed: analyst consensus is bullish with a $117.27 price target, but near-term headwinds from reduced revenue guidance and bearish technical signals pose risks. The stock offers value based on fundamentals, but investor sentiment is cautious following the guidance cut, requiring close monitoring of North American demand trends and AI partnership execution for sustained upside.